Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 11, 2007, Pages 1886-1893

  Fujita, Naoki ^a,b   Sugimoto, Ryosuke ^a   Urawa, Naohito ^a   Araki, Jun ^a   Mifuji, Rumi ^a   Yamamoto, Mika ^a   Horiike, Shinichiro ^a   Tanaka, Hideaki ^a   Iwasa, Motoh ^a   Kobayashi, Yoshinao ^a   Adachi, Yukihiko ^a   Kaito, Masahiko ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization Mie Chuo Medical Center   (Japan)

Author keywords

Chronic hepatitis C; Hepatitis C virus; Interferon; Iron overload; Ribavirin

Indexed keywords

AMINOTRANSFERASE; IRON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; BIOCHEMISTRY; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER HISTOLOGY; LIVER LEVEL; MALE; MONOTHERAPY; MULTIPLE REGRESSION; PREVALENCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGY;

EID: 34948817771     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04759.x     Document Type: Article

References (42)

1. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990 12 : 671 5.
2. Powell E, Edwards-Smit CJ, Hay JL, Goodman Z, Mchutchison J, Albrecht J. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000 31 : 828 33.
3. Poynard T, Rantziu V, Charlotte F et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol. 2001 34 : 730 9.
4. Suzabo G. Pathogenic interactions between alcohol and hepatitis C. Curr. Gastroenterol. Rep. 2003 5 : 86 92.
5. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992 102 : 2108 13.
6. Haque S, Chandra B, Gerber MA, Lok ASF. Iron overload in patients with chronic hepatitis C: a clinicopathologic study. Hum. Pathol. 1996 27 : 1277 81.
7. Hezode C, Cazeneuve C, Coue O et al. Liver iron accumulation in patients with chronic hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J. Hepatol. 1999 31 : 979 84.
8. Tung BY, Emond MJ, Bromer MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003 124 : 318 26.
9. Dabbagh A, Mannion T, Lynch S, Ftei B. The effect of iron overload on rat plasma and liver oxidant status in vivo. Biochem. J. 1994 300 : 799 803.
10. Bassett SE, Di Bisceglie AM, Bacon BR et al. Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Hepatology 1999 29 : 1884 92.
11. Cotler SJ, Emond MJ, Gretch DR et al. Relationship between iron concentration and hepatitis C virus RNA level in liver tissue. J. Clin. Gastroenterol. 1999 29 : 322 6.
12. Kakizaki S, Takagi H, Horiguchi N et al. Iron enhances hepatitis C virus replication in cultured human hepatocytes. Liver 2000 20 : 125 8.
13. Theurl I, Zoller H, Obrist P et al. Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. J. Infect. Dis. 2004 190 : 819 25.
14. Martinelli ALC, Ramalho L, Zucoloto S. Hepatic stellate cells in hepatitis C patients: relationship with liver iron deposits and severity of liver disease. J. Gastroenterol. Hepatol. 2004 19 : 91 8.
15. Farinati F, Cordin R, D'errico A et al. Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclonal antibody MIB1 Ki67 in archival material: the role of etiology, disease activity, iron, and lipid peroxidation. Hepatology 1996 23 : 1468 75.
16. Bonkowsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997 25 : 759 68.
17. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon-α therapy is influenced by the iron content of the liver. J. Hepatol. 1994 20 : 410 15.
18. Olynyk JK, Reddy KR, Di Bisceglie AM et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995 108 : 1104 9.
19. Fontana RJ, Israel J, Leclair P et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000 31 : 730 6.
20. Fargion S, Fracanzani AL, Rossini A et al. Iron reduction and sustained response to interferon-α therapy in patients with chronic hepatitis C: results of Italian multicenter randomized study. Am. J. Gastroenterol. 2002 97 : 1204 10.
21. Guyader D, Boucher E, Andre P et al. A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon. Am. J. Gastroenterol. 1999 94 : 1696 8.
22. Di Bisceglie AM, Bonkovsky HL, Chopra S et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000 32 : 135 8.
23. Alberti A, Alter MJ, Bacon BR et al. National Institutes of Health Consensus Development Conference statement: management of hepatitis C 2002. Hepatology 2002 36 : S3 20.
24. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002 36 : S273 344.
25. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer P. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994 19 : 1513 20.
26. Deugnier YM, Loreal O, Turlin B et al. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 1992 102 : 2050 9.
27. Piperno A, Vergani A, Malosio I et al. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Hepatology 1998 28 : 1105 9.
28. Silvia TSS, Perez RM, Oliveira PV et al. Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study. J. Gastroenterol. Hepatol. 2005 20 : 243 8.
29. George D, Goldwurm S, Macdonald G et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998 114 : 311 18.
30. Weiss G, Umlauft F, Urbanek M et al. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J. Infect. Dis. 1999 180 : 1452 8.
31. Sebastiani G, Vario A, Ferrari A, Pistis R, Noventa F, Aoberti A. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. J. Viral Hepat. 2006 13 : 199 205.
32. Shirazi LK, Datz C, Dobersberger TM et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999 116 : 127 34.
33. Takeo M, Kobayashi Y, Fujita N et al. Upregulation of transferrin receptor 2 and ferroportin 1 mRNA in the liver of patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 2005 20 : 562 9.
34. Rigamonti C, Mottaran E, Reale E et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 2003 38 : 42 9.
35. Chapman RW, Morgan MY, Laulicht M, Hoffbrand AV, Sherlock S. Hepatic iron stores and markers of iron overload in alcoholics and patients with hemochromatosis. Dig. Dis. Sci. 1982 27 : 909 16.
36. Sartori M, Andorno S, Rigamonti C, Grossini E, Nicosia G, Boldorini R. Chronic hepatitis C is mild in menstruating women. J. Gastroenterol. Hepatol. 2000 15 : 1411 17.
37. Yano M, Hayashi H, Yoshioka K et al. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. J. Gastroenterol. 2004 39 : 570 4.
38. Caraceni P, Fagiuoli S, Van Thiel DH. Iron reduction therapy: simply camouflage, or a real weapon. Am. J. Gastroenterol. 1994 89 : 970 2.
39. Farinati RF, Cardin R, Demaria N et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J. Hepatol. 1995 22 : 449 56.
40. Horiike S, Kawanishi S, Kaito M et al. Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C. J. Hepatol. 2005 43 : 403 10.
41. Yano M, Hayashi H, Wakusawa S et al. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am. J. Gastroenterol. 2002 97 : 133 7.
42. Iwasa M, Iwata K, Kaito M et al. Efficacy of long-term dietary restriction of total calories, fat, iron, and protein in patients with chronic hepatitis C. Nutrition 2004 20 : 368 71.